sorafenib with everolimus

Phase 2

MMemorial Sloan Kettering Cancer Center

sorafenib with everolimus is one of 49 therapeutic programs targeting Thyroid Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Thyroid CancerActive, not recruiting

Thyroid CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Lenvima

Eisai

Approved

20 2

Keytruda

Merck & Co.

Approved

9 3

Vitrakvi

Bayer

Approved

3 4

Retevmo

Eli Lilly

Approved

3 5

Gemzar

Nexavar

12 7

Mekinist

Novartis

Phase 3

8 8

Gavreto

RRigel Pharmaceuticals

Approved

3 9

Farydak

SSecuraBio

Approved

—10

Torisel

PPrism Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Thyroid Cancer

NCT01141309

Clinical

Trials by Indication[1]

Thyroid Cancer1 trial

Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01141309·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for sorafenib with everolimus. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for sorafenib with everolimus. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMemorial Sloan Kettering Cancer Center

sorafenib with everolimus

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Thyroid Cancer1 trial

References

Drug Info

Quick Facts

Related News